| Literature DB >> 27320690 |
André E S Simões1, Cecília M P Rodrigues2, Pedro M Borralho3.
Abstract
Conventional mitogen-activated protein kinase (MAPK) family members are among the most sought-after oncogenic effectors for the development of novel human cancer treatment strategies. MEK5/ERK5 has been the less-studied MAPK subfamily, despite its increasingly demonstrated relevance in the growth, survival, and differentiation of normal cells. MEK5/ERK5 signalling has already been proposed to have pivotal roles in several cancer hallmarks, and to mediate the effects of a range of oncogenes. Accumulating evidence indicates the contribution of MEK5/ERK5 signalling to therapy resistance and the benefits of using MEK5/ERK5 inhibitory strategies in the treatment of human cancer. Here, we explore the major known contributions of MEK5/ERK5 signalling to the onset and progression of several types of cancer, and highlight the potential clinical relevance of targeting MEK5/ERK5 pathways.Entities:
Mesh：
Substances：
Year: 2016 PMID： 27320690 DOI： 10.1016/j.drudis.2016.06.010
Source DB: PubMed Journal: Drug Discov Today ISSN： 1359-6446 Impact factor: 7.851